Thus, by expressing FKBP52, the aggregation of Tau protein could be inhibited [15], and such inhibition could form the basis for a treatment of Alzheimer's disease [16]. The gene discussed is FKBP4; the disease is early-onset autosomal dominant Alzheimer disease.